Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $6.75

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $6.75.

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target for the company. Finally, Wall Street Zen cut Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th.

Insiders Place Their Bets

In related news, major shareholder Group Walters bought 4,335,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. The trade was a 32.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ZNTL. AQR Capital Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 177.6% during the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after purchasing an additional 396,233 shares during the period. Millennium Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares during the period. Qube Research & Technologies Ltd bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $37,000. Sei Investments Co. raised its holdings in Zentalis Pharmaceuticals by 373.1% during the 2nd quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after buying an additional 131,780 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after buying an additional 515,257 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $3.83 on Friday. The firm has a market cap of $274.50 million, a P/E ratio of -1.96 and a beta of 1.92. The stock has a 50 day simple moving average of $4.35 and a two-hundred day simple moving average of $3.67. Zentalis Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.